Transaction details
Whitehawk Therapeutics NASDAQ:WHWK disclosed in a Form 4 filing that Chief Executive Officer David James Lennon sold 14,500 shares of the company’s common stock on April 9, 2026. The shares changed hands at $3.38 per share, producing total proceeds of $49,010. Following the sale, Lennon directly holds 518,622 shares of Whitehawk Therapeutics.
The filing states the sale was carried out to satisfy tax withholding obligations arising from the vesting of restricted stock units. The transaction therefore reflects an internal administrative liquidity event tied to equity compensation, rather than an open-market reduction of a discretionary position.
Research presented at SGO 2026
Separately, Whitehawk Therapeutics reported new data presented at the Society of Gynecologic Oncology 2026 Annual Meeting. The company published three posters that examined expression patterns of MUC16 in ovarian and endometrial cancers. The analysis was performed in collaboration with Tempus AI.
According to the posters, MUC16 expression in ovarian cancer is markedly higher than for other antibody-drug-conjugate targets referenced in the presentations - with reported differences ranging from 2-fold to over 100-fold. The posters also indicate MUC16 expression remains stable across disease stages and clinical variables cited in the materials, including metastatic status and platinum sensitivity. The data highlighted that high-grade serous ovarian carcinoma - which the presentation cited as comprising about 70% of ovarian cancer cases - shows consistent MUC16 expression.
Valuation note and resources
An InvestingPro analysis referenced alongside the filing indicates Whitehawk Therapeutics appears undervalued at current trading levels. The company is covered in a Pro Research Report available through the platform, which the notice says is part of a broader coverage universe exceeding 1,400 U.S. equities.
What this means
The insider sale was disclosed promptly via Form 4 and was specifically linked to tax withholding on vested restricted stock units. Separately, the scientific presentations emphasize elevated and apparently stable MUC16 expression in ovarian cancer samples, a detail the company notes could be relevant to therapeutic strategies targeting MUC16. The materials do not claim clinical efficacy or link the expression data to any completed or ongoing therapeutic outcomes.
Limitations: The Form 4 describes the mechanics of the share sale and the company presentations report expression findings; neither source in the filing or presentation establishes clinical results or definitive commercial outcomes.